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Abstract
Medical device manufacturers must contin -
uously evaluate all clinical data available for
their products marketed in Europe. With the
European Medical Device Regulation
2017/745 coming into force in May 2021,
manufacturers are required to assess available
implant registry data as part of the clinical
evaluation process. This new requirement will
necessitate a closer collaboration between
industry and registries to evaluate the safety
and performance of high-risk devices.
Medical writers should be aware of existing
implant registries, understand what charac -
teristics make a registry suitable to support
regulatory requirements, and recognise both
the value and the limitations of registries as a
source of clinical evidence.
Patient registries provide a rich source of data on
specific diseases, conditions, treatments, and
exposures. Registry data are used to evaluate real-
world treatments and outcomes, compare safety
and effectiveness of treatments, monitor long-
term safety, identify risk factors, and to assess
quality in health care systems. Although
randomised controlled trials are considered the
gold standard for evaluating most medical
treatments, it is not always feasible or ethical to
carry them out on medical devices. Registries are
increasingly seen as a supplement to data from
randomised clinical trials, and in some cases, may
be the only feasible approach to evaluate the
long-term safety of some implantable devices. 
The push to make better use of registry data for
device surveillance increased as serious concerns
about medical device safety came to light in 2012,
specifically around the use of non-medical grade
silicone in breast implants by Poly Implant
Prothèse. This led the European Com mission and
EU countries to establish a joint action plan ( Joint
Plan for Immediate Actions under existing
Medical Devices Legislation).1 One of the five
“immediate actions” was to support the
development of implant registries that could
identify safety issues and allow for long-term
monitoring of safety and performance. Further
implant safety issues making headlines in recent
years, such as those related to metal-on-metal hip
implants and vaginal mesh, only increased the
pressure for heightened oversight and surveillance
of medical devices, including calls for compulsory
registration of all implantable devices.2
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The European Medical Device Regulation
(MDR) 2017/745 is the first regulation to
include a specific requirement to evaluate registry
data.3 Article 108 of the MDR encourages
the establishment of registries and
registry networks based on
common principles that enable
the collection of comparable data
on the long-term safety and
performance of devices. It also
suggests that registries contribute
to traceability of implantable
devices. In addition, the MDR
requires both manufacturers and noti -
fied bodies to consider registry data as part of
their obligations. Annex III (1.1 (a)) lays out the
requirements to consider relevant databases and
registries as part of post-market surveillance
plans, while Annex VII (4.11(h)) requires an
assessment of data from registries to be
considered for re-certification by notified bodies. 
What is an implant registry?
The International Medical Device Regulator
Forum defines a medical device registry as an “an
organized system with a primary aim to increase
the knowledge on medical devices contributing
to improve the quality of patient care that
continuously collects relevant data, evaluates
meaningful outcomes and comprehensively
covers the population defined by exposure to
particular device(s) at a reasonably generalizable
scale (e.g., international, national, regional, and
health system).”4 Registries use observational
methods to collect standardised data on a
population defined by a specific disease or
condition (e.g., multiple sclerosis registry) or
treatment with a specific product or procedure
(e.g., arthroplasty registries). They may operate
internationally, nationally, regionally, or at a
single healthcare institution.5 Many implant
registries are led by professional medical societies
or consortia. Implant registries collect more than
just information about implants and include
detailed information about patient characteristics
and clinical outcomes. 
Identifying implant registries 
Keeping a complete and up-to-date overview of
all operating implant registries is challenging.
Generally well-established and long-standing
national registries, such as the Swedish Knee
Arthroplasty Register operating since 1975, the
NJR (National Joint Registry) since 2002 in the
UK, or SIRIS (Swiss National Joint Registry)
since 2012, are easy to identify and will have the
most valuable data in terms of quantity and
quality. Smaller and newer registries may be
identified through professional medical
societies. Systematic reviews have
been undertaken to map the
implant registry landscape in
Europe.6,7 In 2013 researchers
identified 101 implant registries
in Europe and found that most
are concentrated in the fields of
cardiology (38 registries) and ortho -
paedics/arthroplasty (29 registries).7 
A later review published in 2017 identified 24
hip and knee replacement registries in Europe.6
Registries dedicated to other types of devices
were less common: pacemakers and heart stents,
breast implants, cochlear implants, insulin
pumps, tubes, other stents, ophthalmological
devices, brain stimulation/shunts, sacral neuro -
modulation, drug depots, and dental implants.7
Another approach to identifying an appropriate
registry is to search a registry of patient registries.
The EMA inventory of registries maintained by
the ENCePP (European Network of Centres for
Pharmacoepidemiology and Pharma covigilance)8
and the cross-border PARENT (PAtient
REgistries iNiTiative)9 list of registries of Europe
are two such initiatives that aim to increase
transparency, avoid duplication, and promote
collaboration among registries. 
What kind of data can
implant registries supply?
Registries can supply data at the level of the
patient, implant, healthcare provider, and
healthcare clinic, all factors that can influence
clinical outcomes. Typical types of data collected
include patient demographics (e.g., age, sex, co-
morbidities), procedure details (e.g., type of
surgery, surgical approach, surgery duration),
clinical data (e.g., indication, diagnosis, previous
interventions), patient follow-up, adverse events,
and implant details (e.g., UDI-DI [Unique
Device Identification-Device Identifier] and
device characteristics). However, more variables
are not necessarily better, and the overall burden
on data providers needs to be considered.
Registries that collect fewer variables with an easy
and quick procedure may better ensure the
continued motivation of the data providers and
a higher level of data quality. When assessing the
appropriateness of an implant registry as a source
of clinical evidence, the use of harmonised
implant categorisation, patient-reported outcomes,
and the ability of the registry to link to other data
sources are especially important aspects to
consider. 
Implant data
Historically, registry data collection focussed on
treatment procedures and outcomes in clinical
files and patient records. With increasing use of
implants, the focus shifted to device-related
outcomes. To enable meaningful comparisons
between similar implants, registries characterise
each implant by collecting detailed information
on product characteristics such as type, size,
shape, material, coatings, or other important
attributes. Several initiatives at the European level
as well as globally have led to harmonised
classification systems for orthopaedic implants,
an important step to enable comparisons
between registries. The implant library developed
by the EPRD (German Arthroplasty Registries)
and adopted by the NJR,10,11 and the ISAR
(International Society of Arthroplasty Registries)
International Prosthesis Library12 are examples
of such efforts. In the example of arthroplasty, the
use of a standard implant classification to analyse
revision rates and implant survival is a
prerequisite for a registry to serve as an early
warning system for implant failures. 
Patient-reported outcomes
The patient’s subjective evaluation of healthcare
outcomes using patient-reported outcome
measures (PROMs) has gained recognition in
value-based healthcare assessment. In quality
assessment studies, patients are asked to com -
plete a PROM questionnaire before a surgical
intervention – for example about levels of pain,
difficulties in daily activities, work-related limit -
ations due to a health issue, and effects on social
activities and family. After surgery, the same
questionnaire completed by the patient at a
specified follow-up time or multiple times (e.g.,
at 6 months and 1 year) is compared with the
baseline measures to assess if the intervention
was successful. Many registries are incorporating
PROMs and recognise that these outcomes
complement the clinical outcomes. 
Enriched data through linkage
Data collection for registries adds to the
administrative workload of health workers, and
registries should be designed with only the
The
MDR requires
both manufacturers
and notified bodies to
consider registry data 
as part of their
obligations.
minimal information needed. Registries that are
able to capture identifying patient information,
where legal regulations and informed consents
allow, enable future linkage to external datasets
and reduce the burden on the registry data
provider. For example, information about a
patient’s vital status (i.e., dead, alive, emigrated,
or unknown) is crucial to calculate accurate
revision rates in arthroplasty but is generally not
available in registry data. Linkage of registry data
with routinely collected administrative data, like
mortality data, can overcome this limitation.
Linkage to other types of datasets enrich the
registry data and can facilitate analyses of
important topics such as cost-effectiveness.
Furthermore, electronic patient records or data
of healthcare insurances are rich sources of
information for quality assessment and research.
Suitability of implant
registries for regulatory
submissions
The availability of relevant data from a registry is
just one aspect to consider when assessing the
suitability of a registry to provide clinical
evidence. The International Medical Device
Regulator Forum Registry Working Group has
defined 15 registry requirements, grouped into
six elements, to assess the suitability of registry
data for regulatory submissions (Table 1). The
importance of each element is weighted
differently depending on the intended use of the
data. For example, the use of controlled vocab -
ularies is recommended for post-market sur -
veillance, while it is highly recommended for data
intended to support an initial device approval or
indication expansion.13 Additional aspects that
merit consideration are the complete ness of data
collection, transparent quality assurance
processes, a clear policy for data access and
sharing, and registry sustainability.14 
An example – the Swiss
National Implant Registry
SIRIS began registering hip and knee implants in
September 2012 and is now the largest implant
registry in Switzerland, with data collection
supported by 186 healthcare institutions.
Participation is compulsory for all hospitals and
clinics performing knee and hip arthroplasties.
The registry included 90%–92% of all hip and
knee replacement procedures occurring in
Switzerland, according to the most recent
coverage estimates.15 In the SIRIS 2019 annual
report, implant types and brands have been
compared for the first time using an implant
library based on product catalogues from
industry partners. In arthroplasty, the implant
revision rate is the main outcome of interest. 
A revision procedure occurs when a patient’s
primary hip or knee primary implant is replaced
by new components. 
Figure 1 shows an example of the kind of
analysis that can be performed with registry data
with sufficiently detailed implant data collection.
The funnel plot shows the 2-year revision rates
for each participating health service unit by
volume of performed operations. This analysis
identifies clinics with revision rates outside of the
expected variability by chance. A second type of
analysis of specific product brands can identify
“outlier” devices or device combinations that
have a higher than expected revision rate than
similar benchmark devices (Figure 2). However,
because registries use observational study
methods, many factors could contribute to an
outlier status such as patient selection, case-mix,
surgical technique, surgeon experience, and
health service character istics. The initial analysis
shown in Figure 2 provides an alert that initiates
a more in-depth analysis of the underlying cause
of a poor outcome.16 
Challenges with implant
registry data 
There are many challenges associated with
registry data collection, and many are not limited
specifically to implant registries. Case coverage,
completeness, and data quality are relevant for all
types of registries. High quality medical device
data collection poses a unique challenge to
implant registries as well as disease registries that
attempt to collect implant data. 
Coverage and completeness
To answer questions about quality of health care
treatments or safety of medical devices using
registry data, careful evaluation of potential
sources of bias is paramount. High external
validity, especially when compared with ran -
domised clinical trials, is an important advantage
of registries. Results from registry data are
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Table 1. Registry elements affecting the suitability of clinical data for regulatory use 
Element                                                               Registry requirements
Governance                                                   l Transparent governance structure and processes
Quality management system                   l Legal requirements for data collection and handling are met
                                                                          l Information on patient data protection
                                                                          l Policy on access to data
                                                                          l Essential information available for verification 
(e.g., by competent authority, notified body)
Data gathering                                              l Relevant variables
                                                                          l Unambiguous device identification (e.g., UDI system)
                                                                          l Ability to link with other data sources
                                                                          l Use of controlled vocabularies 
                                                                          l Use of harmonised minimum data model
Data storage                                                  l Security protection against hacking, altering, deleting, 
or stealing data
Methodology/data analysis                     l Conduct of analyses across different types of analysis
frameworks
                                                                          l Data interpretation
Transparency/display/                             l Publicly available reports; report frequency and content
distribution                                                   l Publicly accessible website and web-reporting
Adapted from the International Medical Device Regulator Forum Registry Working Group.13 
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Figure 1. Example clinic analysis from SIRIS: Two-year revision rate of primary total hip arthroplasty by health care service
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Combination                                                              N                        N                                          %**
                                                                           revised            at risk* 0  2  4  6  8  10  12  14  16  18  20  22  24  
Exception + Betacup                                             1                    50
Fitmore + RM pressfit vitamys                       11                  551
Harmony + April Ceramic                                  1                     50
AMIStem + Versafitcup System                     21                  992
Alloclassic + Alloclassic                                       3                  142
SL-plus + HI                                                         10                  468
Polarstem + Polarcup                                         19                  882
SBG + R3                                                                  9                  405
Corail + RM pressfit                                             2                     88
Quadra + Versafitcup CC Trio                       51                2278
Optimys + Allofit                                                   3                  134
Corail + Pinnacle                                              167               7124
Exception + Avantage                                           8                  339
Quadra + Versafitcup System                         10                  416
AMIStem + Versafitcup CC Trio                 145               5796
Avenir + Allofit                                                  105                4164
SL-Plus + EP-fit                                                   15                  581
CLS + Allofit                                                         25                  895
CLS + Fitmore                                                     28                1019
Corail + Allofit                                                        3                  107
Twinsys + RM pressfit vitamys                       41                1485
Accolade + Trident                                               2                     68
Exception + Exceed                                               3                     99
Fitmore + Allofit                                               100                3301
* Number of patients with at least two years follow-up (i.e. primary prosthesis in 2012–2016).
** Rates ajusted for effects of mortality and emigration.
Figure 2. Example benchmark analysis
from SIRIS: Two-year revision rates of
uncemented stem-cup combinations used
in primary total hip arthroplasty 
(2012–2018). 
Reprinted with permission from:
SIRIS. (2019). SIRIS Report 2019: Annual Report of
the Swiss National Joint Registry, Hip and Knee, 
2012 – 2018. 15
Reprinted with permission from: SIRIS. (2019). SIRIS Report 2019: 
Annual Report of the Swiss National Joint Registry, Hip and Knee, 2012 – 2018. 15
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generalisable if several conditions are met. 
A national registry needs to include all health
services in the country delivering the treatment
in focus. Underrepresentation of some areas or
types of health services may introduce bias.
Within a healthcare facility, all procedures
meeting the inclusion criteria for the registry
need to be recorded for full coverage. Excluding
services or complex cases leads to bias in the
analyses, interpretation of data, and general -
isability. To calculate many outcome measures
(e.g., the revision rate from arthroplasty
registries), detailed knowledge about the
registry coverage is vital. For example,
if an implant revision surgery is
performed in a clinic that does
not record the operation in the
registry, the revision rate will be
under esti mated. Another
condition for unbiased analyses
is the completeness of data. For
the complete recording of im -
plants, smart implant interfaces are
needed. The type of oper ation (e.g., total
hip arthroplasty) defines the expected type and
number of implants and can be tracked during
the scanning process. Warnings and error
messages help to ensure that all expected
implants for each case are captured.
Data quality 
Several measures help to ensure and evaluate the
quality of data and results: 
1. use of reference data, sales figures, insurance
data, or routinely collected administrative
data to estimate the coverage of the registry, 
2. precise definitions of inclusion and exclusion
criteria for the registry, and 
3. thoughtful design of electronic data capture
forms, with precise definitions of variables,
ranges of valid data, distinct categories of
answers, mandatory and optional fields, and
handling of potential missing data.
Measures for high registry data quality, coverage,
completeness, and correctness can be
implemented during different phases of the
registry data capture process. Variable definitions,
inclusion and exclusion criteria, and validation
rules are defined before the data entry. During
data entry, registry system rules provide warnings
and errors, and first level support teams help with
completing data entry forms. After data entry,
automated monitoring routines and plausibility
checks help detect potential errors or incon -
sistent data entries. Finally, for registries with
sufficient funding, monitoring visits in the clinics
and standardised audits verify the correctness of
the data entered by comparing the source
information in the clinical records with data
captured in the registry.
Implant libraries
To access usable data for manufacturers to fulfil
clinical evidence requirements, many registries
do not have sufficiently detailed data collection
to enable sophisticated analyses of specific
implants. For example, some registries
may collect data on general types of
medical devices or implants used
(e.g., plates, screws, external
fixator) but not details that
allow identification of a specific
brand, model, or reference
number. Another challenge is
implementing a standardised
categorisation of implants so that
data may be compared across registries.
Recent international congresses and meet ings,
for example the International Society of
Arthroplasty Registries conferences, have
advanced the discussion about standardi sation
and harmonisation of implant libraries. This led
to agreements between the NJR in the UK and
the German EPRD to harmonise their existing
implant library definitions. Keeping these
libraries up-to-date and accurate requires
commitment from industry, with manufacturers
needed to classify existing and newly marketed
products according to a standard system with
sufficient granularity that meaningful data
analysis can happen.
In the future, the standardisation of implant
libraries will reduce the administrative burden for
manufacturers who provide implant catalogues
with different categories and levels of granularity
for different registries in many different
countries. Ideally, implant registries may update
their implant libraries using comprehensive
implant data warehouses such as EUDAMED
(European Database on Medical Devices) or
other international databases. Unfortunately,
local legal regulations leading to products sold in
some but not other countries and challenges in
standardisation processes hamper the
development of international implant registries.
Conclusion
An increasing focus on the role and value of
registries has led to steps to encourage better
integration of registry data into regulatory decision
making.16,17 This effort requires the collaboration
and input of all registry stake holders, including
patients, health care providers, professional
societies, registry custodians, researchers, reim -
bursement bodies, public health and regulatory
bodies, and the medical device industry. It is
important to ensure that registries used to support
regulatory requirements are well designed to
produce valid data. The medical writer will play an
important role in com municating clinical evidence
on devices generated from registry data.
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